Cited by 441Cancer Immunotherapy and BiomarkersInflammatory Biomarkers in Disease PrognosisFerroptosis and cancer prognosis

The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.

Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors

Open access

Valero, Cristina, Lee, Mark, Hoen, Douglas, Weiss, Kate, Kelly, Daniel W., Adusumilli, Prasad S., Paik, Paul K., Plitas, George, Ladanyi, Marc, Postow, Michael A., Ariyan, Charlotte E., Shoushtari, Alexander N., Balachandran, Vinod P., Hakimi, A. Ari, Crago, Aimee M., Long Roche, Kara C., Smith, J. Joshua, Ganly, Ian, Wong, Richard J., Patel, Snehal G., Shah, Jatin P., Lee, Nancy Y., Riaz, Nadeem, Wang, Jingming, Zehir, Ahmet, Berger, Michael F., Chan, Timothy A., Seshan, Venkatraman E., Morris, Luc G. T.·2021·Nature Communications

DOI 10.1038/s41467-021-20935-9PMC PMC7851155

Open this paper in CoChat — free account Open PDF

Abstract

Treatment with immune checkpoint inhibitors (ICI) has demonstrated clinical benefit for a wide range of cancer types. Because only a subset of patients experience clinical benefit, there is a strong need for biomarkers that are easily accessible across diverse practice settings. Here, in a retrospective cohort study of 1714 patients with 16 different cancer types treated with ICI, we show that higher neutrophil-to-lymphocyte ratio (NLR) is significantly associated with poorer overall and progression-free survival, and lower rates of response and clinical benefit, after ICI therapy across multiple cancer types. Combining NLR with tumor mutational burden (TMB), the probability of benefit from ICI is significantly higher (OR = 3.22; 95% CI, 2.26-4.58; P < 0.001) in the NLR low/TMB high group compared to the NLR high/TMB low group. NLR is a suitable candidate for a cost-effective and widely accessible biomarker, and can be combined with TMB for additional predictive capacity.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/s41467-021-20935-9

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Fig. 1 Pan-cancer outcomes based on neutrophil-to-lymphocyte ratio (NLR). a Overall survival, b progression-free survival, c response, and d clinical benefit at a pan-cancer level based on high vs. low NLR. The cutoff was the top 20th percentile within each cancer type. P-values are according to log-rank test for a and b, and Pearson’s χ2-test for c and d.CC BY · PubMed Central

Fig. 2 Outcomes based on neutrophil-to-lymphocyte ratio (NLR) stratified by cancer type. Forest plots showing hazard ratios (HRs) with 95% CIs for a overall survival and b progression-free survival across cancer types, comparing top 20th NLR percentile within each cancer type to bottom 80th. HRs were calculated with Cox proportional hazard regression. Abreviations: OS, overall survival; Haz. Ratio, hazard ratio; CI, confidence interval; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; PFS, progression-free survival.CC BY · PubMed Central

Fig. 3 Pan-cancer outcomes according to a combined neutrophil-to-lymphocyte ratio (NLR) and tumor mutational burden (TMB) categorization. a Overall survival, b progression-free survival, c response, and d clinical benefit at a pan-cancer level. Patients were classified into four categories based on NLR low/high and TMB low/high, using median within cancer type as cutoff for both variables. P-values are according to log-rank test for a and b, and Pearson’s χ2-test for c and d.CC BY · PubMed Central

Fig. 4 Outcomes across quartile-based categories of neutrophil-to-lymphocyte ratio (NLR) and tumor mutational burden (TMB). Heat maps of hazard ratios (HRs) for a overall survival and b progression-free survival, and heat maps of odds ratios (ORs) for c response and d clinical benefit based on 16 within cancer type quartile-based categories of NLR and TMB. HRs were calculated with Cox proportional hazard regression. ORs were calculated with logistic regression.CC BY · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Samstein, R. M., Lee, C.-H., Shoushtari, A. N., Hellmann, M. D., Shen, R., Janjigian, Y. Y., Barron, D. A., Zehir, A., Jordan, E. J., Omuro, A., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0312-8 · Cited by 4,071
Self-citation
Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis
Templeton, A. J., McNamara, M. G., Šeruga, B., Vera-Badillo, F. E., Aneja, P., Ocaña, A., Leibowitz-Amit, R., Sonpavde, G., Knox, J. J., Tran, B., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju124 · Cited by 2,829
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
Cristescu, R., Mogg, R., Ayers, M., Albright, A., Murphy, E., Yearley, J., Sher, X., Liu, X. Q., Lu, H., Nebozhyn, M., et al. (2018) · Science · doi:10.1126/science.aar3593 · Cited by 2,301
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Havel, J. J., Chowell, D., & Chan, T. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0116-x · Cited by 2,286
Self-citation
Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)
Cheng, D. T., Mitchell, T. N., Zehir, A., Shah, R. H., Benayed, R., Syed, A., Chandramohan, R., Liu, Z. Y., Won, H. H., Scott, S. N., et al. (2015) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2014.12.006 · Cited by 2,119
Self-citation

Show all 57 references

Research works printed but not linked: 1

Amin, M. B. et al. AJCC Cancer Staging Manual (Springer, 2017).

Sorted by citations

Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
Passaro, A., Bakir, M. A., Hamilton, E. G., Diehn, M., André, F., Roy‐Chowdhuri, S., Mountzios, G., Wistuba, I. I., Swanton, C., & Peters, S. (2024) · Cell · doi:10.1016/j.cell.2024.02.041 · Cited by 726
Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1
McCulloch, J. A., Davar, D., Rodrigues, R. R., Badger, J. H., Fang, J. R., Cole, A. M., Balaji, A. K., Vetizou, M., Prescott, S. M., Fernandes, M. R., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01698-2 · Cited by 472
Improved prediction of immune checkpoint blockade efficacy across multiple cancer types
Chowell, D., Yoo, S., Valero, C., Pastore, A., Krishna, C., Lee, M., Hoen, D. R., Shi, H., Kelly, D. W., Patel, N., et al. (2021) · Nature Biotechnology · doi:10.1038/s41587-021-01070-8 · Cited by 275
Self-citation
TMB or not TMB as a biomarker: That is the question
Addeo, A., Friedlaender, A., Banna, G. L., & Weiss, G. J. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103374 · Cited by 224
Immune Checkpoint Inhibitor Therapy in Oncology
Tan, S., Day, D., Nicholls, S. J., & Segelov, E. (2022) · JACC CardioOncology · doi:10.1016/j.jaccao.2022.09.004 · Cited by 219
Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy
Hwang, M., Canzoniero, J. V., Rosner, S., Zhang, G., White, J. R., Belcaid, Z., Cherry, C., Balan, A., Pereira, G., Curry, A., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004688 · Cited by 150
Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance
Guo, C. W., Sharp, A., Gürel, B., Crespo, M., Figueiredo, I., Jain, S., Vogl, U. M., Rekowski, J., Rouhifard, M., Gallagher, L., et al. (2023) · Nature · doi:10.1038/s41586-023-06696-z · Cited by 149
Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy
Wang, Y., Johnson, K. C. C., Gatti-Mays, M. E., & Li, Z. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01335-y · Cited by 137
Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data
Yoo, S., Fitzgerald, C. W. R., Cho, B. A., Fitzgerald, B. G., Han, C. Y., Koh, E. S., Pandey, A., Sfreddo, H. J., Crowley, F., Rudshteyn, M., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03398-5 · Cited by 159
Self-citation
Neutrophils and polymorphonuclear myeloid-derived suppressor cells: an emerging battleground in cancer therapy
Raskov, H., Orhan, A., Gaggar, S., & Gögenür, I. (2022) · Oncogenesis · doi:10.1038/s41389-022-00398-3 · Cited by 137
Systemic Immune–Inflammation Index Predicts Prognosis of Cancer Immunotherapy: Systemic Review and Meta-Analysis
Tian, B., Yang, Y., Yang, C., Yan, L., Ding, Z., Liu, H., Xue, J.-S., Dong, Z., Chen, Z., Hong, J., et al. (2022) · Immunotherapy · doi:10.2217/imt-2022-0133 · Cited by 139
LORIS robustly predicts patient outcomes with immune checkpoint blockade therapy using common clinical, pathologic and genomic features
Chang, T., Cao, Y., Sfreddo, H. J., Dhruba, S. R., Lee, S., Valero, C., Yoo, S., Chowell, D., Morris, L. G. T., & Ruppin, E. (2024) · Nature Cancer · doi:10.1038/s43018-024-00772-7 · Cited by 149
Self-citation
The role of biomarkers in personalized immunotherapy
Sankar, K., Ye, J. C., Li, Z., Zheng, L., Song, W., & Hu-Lieskovan, S. (2022) · Biomarker Research · doi:10.1186/s40364-022-00378-0 · Cited by 111
Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer
Alessi, J. V., Ricciuti, B., Alden, S. L., Bertram, A. A., Lin, J. J., Sakhi, M., Nishino, M., Vaz, V. R., Lindsay, J. R., Turner, M. M., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003536 · Cited by 105
Peripheral blood inflammatory biomarkers dynamics reflect treatment response and predict prognosis in non‐small cell lung cancer patients with neoadjuvant immunotherapy
Huai, Q., Luo, C., Song, P., Bie, F., Bai, G., Li, Y., Liu, Y., Chen, X., Zhou, B., Sun, X., et al. (2023) · Cancer Science · doi:10.1111/cas.15964 · Cited by 109
The GPCR–Gαs–PKA signaling axis promotes T cell dysfunction and cancer immunotherapy failure
Wu, V. H., Yung, B. S., Faraji, F., Saddawi‐Konefka, R., Wang, Z., Wenzel, A. T., Song, M., Pagadala, M. S., Clubb, L. M., Chiou, J., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01529-7 · Cited by 101
Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: challenges and opportunities
Wang, X., Lamberti, G., Federico, A. D., Alessi, J. V., Ferrara, R., Sholl, M. L., Awad, M. M., Vokes, N. I., & Ricciuti, B. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.03.007 · Cited by 99
Mitochondrial DNA mutations drive aerobic glycolysis to enhance checkpoint blockade response in melanoma
Mahmood, M., Liu, E. M., Shergold, A. L., Tolla, E., Tait-Mulder, J., Uribe, A. H., Shokry, E., Young, A. L., Lilla, S., Kim, M., et al. (2024) · Nature Cancer · doi:10.1038/s43018-023-00721-w · Cited by 101
Association between immune-related adverse event timing and treatment outcomes
Hsiehchen, D., Naqash, A. R., Espinoza, M., von Itzstein, M. S., Cortellini, A., Ricciuti, B., Owen, D. H., Laharwal, M., Toi, Y., Burke, M., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2021.2017162 · Cited by 93
Neutrophil-to-Lymphocyte Ratio (NLR) in NSCLC, Gastrointestinal, and Other Solid Tumors: Immunotherapy and Beyond
Mosca, M., Nigro, M. C., Pagani, R., Giglio, A. D., & Federico, A. D. (2023) · Biomolecules · doi:10.3390/biom13121803 · Cited by 100
The evolution and heterogeneity of neutrophils in cancers: origins, subsets, functions, orchestrations and clinical applications
Liu, S., Wu, W., Du, Y., Yin, H., Chen, Q., Yu, W., Wang, W., Yu, J., Liu, L., Lou, W., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01843-6 · Cited by 93
Single cell and spatial transcriptomics highlight the interaction of club-like cells with immunosuppressive myeloid cells in prostate cancer
Kiviaho, A., Eerola, S. K., Kallio, H. M. L., Andersen, M. K., Hoikka, M., Tiihonen, A. M., Salonen, I., Spotbeen, X., Giesen, A., Parker, C. T. A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54364-1 · Cited by 97
Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity
Ma, X., Riaz, N., Samstein, R. M., Lee, M., Makarov, V., Valero, C., Chowell, D., Kuo, F., Hoen, D. R., Fitzgerald, C. W. R., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01108-w · Cited by 87
Self-citation
Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAF V600E -Mutated Anaplastic Thyroid Carcinoma
Hamidi, S., Iyer, P. C., Dadu, R., Gule-Monroe, M. K., Maniakas, A., Zafereo, M., Wang, J. R., Busaidy, N. L., & Cabanillas, M. E. (2024) · Thyroid · doi:10.1089/thy.2023.0573 · Cited by 84
Self-citation
γδ T Cells in the Tumor Microenvironment—Interactions With Other Immune Cells
Chan, K. F., Duarte, J. D. G., Ostrouska, S., & Behren, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.894315 · Cited by 82
KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup
Xie, M., Xu, X., & Fan, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.672612 · Cited by 80
Distinct Mechanisms of Mismatch Repair Deficiency Delineate Two Modes of Response to PD-1 Immunotherapy in Endometrial Carcinoma
Chow, R. D.-W., Michaels, T., Bellone, S., Hartwich, T. M. P., Bonazzoli, E., Iwasaki, A., Song, E., & Santin, A. D. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0686 · Cited by 78
Predictive biomarkers for immune-related adverse events in cancer patients treated with immune-checkpoint inhibitors
Wang, J., Ma, Y., Lin, H., Wang, J., & Cao, B. (2024) · BMC Immunology · doi:10.1186/s12865-024-00599-y · Cited by 72
Self-citation
Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung Cancer
Daniello, L., Elshiaty, M., Bozorgmehr, F., Kuon, J., Kazdal, D. N., Schindler, H., Shah, R., Volckmar, A., Lusky, F., Diekmann, L., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.703893 · Cited by 70
Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy
Wang, S. L., & Chan, T. A.-T. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.03.006 · Cited by 80
Self-citation
Baseline and early changes in the neutrophil–lymphocyte ratio (NLR) predict survival outcomes in advanced colorectal cancer patients treated with immunotherapy
Ouyang, H., Xiao, B., Huang, Y., & Wang, Z. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110703 · Cited by 70
Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial
Vos, J. L., Burman, B., Jain, S., Fitzgerald, C. W. R., Sherman, E. J., Dunn, L. A., Fetten, J. V., Michel, L. S., Kriplani, A., Ng, K., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02518-x · Cited by 63
Self-citation
The predictive value of inflammatory biomarkers for major pathological response in non-small cell lung cancer patients receiving neoadjuvant chemoimmunotherapy and its association with the immune-related tumor microenvironment: a multi-center study
Li, C., Wu, J., Jiang, L., Zhang, L., Huang, J., Tian, Y., Zhao, Y., Liu, X., Xia, L., Haoran, E., et al. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03262-w · Cited by 62
Immunotherapy in melanoma: Can we predict response to treatment with circulating biomarkers?
Splendiani, E., Besharat, Z. M., Covre, A., Maio, M., Giacomo, A. M. D., & Ferretti, E. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108613 · Cited by 62
Neutrophil‐to‐lymphocyte ratio as a prognostic marker for head and neck squamous cell carcinoma treated with immune checkpoint inhibitors: Meta‐analysis
Takenaka, Y., Oya, R., Takemoto, N., & Inohara, H. (2022) · Head & Neck · doi:10.1002/hed.26997 · Cited by 64
Thyroid-related adverse events induced by immune checkpoint inhibitors
Chera, A., Stancu, A. L., & Bucur, O. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1010279 · Cited by 62
Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors
Zarif, T. E., Nassar, A. H., Pond, G. R., Zhuang, T., Master, V. A., Nazha, B., Niglio, S. A., Simon, N. I., Hahn, A. W., Pettaway, C. A., et al. (2023) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djad155 · Cited by 60
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from a German real‐world cohort
Jost‐Brinkmann, F., Demir, M., Wree, A., Luedde, T., Loosen, S. H., Müller, T., Tacke, F., Roderburg, C., & Mohr, R. U. (2023) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17441 · Cited by 59
From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades
Zhao, X., Bao, Y., Meng, B., Xu, Z., Li, S., Wang, X., Hou, R., Ma, W., Liu, D., Zheng, J., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.920021 · Cited by 58
Machine learning for prediction of immunotherapeutic outcome in non-small-cell lung cancer based on circulating cytokine signatures
Wei, F., Azuma, K., Nakahara, Y., Saito, H., Matsuo, N., Tagami, T., Kouro, T., Igarashi, Y., Tokito, T., Kato, T., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-006788 · Cited by 58
Focus on the Dynamics of Neutrophil-to-Lymphocyte Ratio in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Meta-Analysis and Systematic Review
Guo, Y., Xiang, D., Wan, J., Yang, L., & Zheng, C. (2022) · Cancers · doi:10.3390/cancers14215297 · Cited by 63
Association of high-risk stigmata and worrisome features with advanced neoplasia in intraductal papillary mucinous neoplasms (IPMN): A systematic review
Ohno, E., Balduzzi, A., Hijioka, S., Pastena, M. D., Marchegiani, G., Kato, H., Takenaka, M., Haba, S., & Salvia, R. (2023) · Pancreatology · doi:10.1016/j.pan.2023.12.002 · Cited by 55
Pretreatment neutrophil-to-lymphocyte ratio is associated with immunotherapy efficacy in patients with advanced cancer: a systematic review and meta-analysis
Su, J., Yu-ning, L., Tan, S., Cheng, T., Luo, Y., & Zhang, L. (2025) · Scientific Reports · doi:10.1038/s41598-024-84890-3 · Cited by 60
Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols
Cottrell, T. R., Lotze, M. T., Ali, A. M., Bifulco, C. B., Capitini, C. M., Chow, L. Q. M., Cillo, A. R., Collyar, D. E., Cope, L., Deutsch, J. S., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010928 · Cited by 65
Immunomodulatory effects of G-CSF in cancer: Therapeutic implications
Mouchemore, K. A., & Anderson, R. L. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101512 · Cited by 58
Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition
Alvarez-Breckenridge, C. A., Markson, S. C., Stocking, J. H., Nayyar, N., Lastrapes, M., Strickland, M. R., Kim, A. E., de Sauvage, M. A., Dahal, A., Larson, J. M., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0870 · Cited by 55
Primary and Acquired Resistance to Immunotherapy with Checkpoint Inhibitors in NSCLC: From Bedside to Bench and Back
Mariniello, A., Borgeaud, M., WEINER, M. H., Frisone, D., Kim, F., & Addeo, A. (2025) · BioDrugs · doi:10.1007/s40259-024-00700-2 · Cited by 61
Versatile neutrophil functions in cancer
Siwicki, M. R., & Pittet, M. J. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101538 · Cited by 52
Efficacy and Safety of TACE Combined With Lenvatinib Plus PD-1 Inhibitors Compared With TACE Alone for Unresectable Hepatocellular Carcinoma Patients: A Prospective Cohort Study
Qu, S., Zhang, X., Wu, Y., Meng, Y., Pan, H., Fang, Q., Hu, L., Zhang, J., Wang, R., Wei, L., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.874473 · Cited by 52
Immunotherapy-related biomarkers: Confirmations and uncertainties
Catalano, M., Iannone, L. F., Nesi, G., Nobili, S., Mini, E., & Roviello, G. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104135 · Cited by 61
Association of Dynamic Changes in Peripheral Blood Indexes With Response to PD-1 Inhibitor-Based Combination Therapy and Survival Among Patients With Advanced Non-Small Cell Lung Cancer
Chen, Y., Wen, S., Xia, J., Du, X., Wu, Y., Pan, B., Zhu, W., & Shen, B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.672271 · Cited by 51
Progresses in biomarkers for cancer immunotherapy
Lin, X., Zong, C., Zhang, Z., Fang, W., & Xu, P. (2023) · MedComm · doi:10.1002/mco2.387 · Cited by 50
Tumor-associated neutrophils suppress CD8+ T cell immunity in urothelial bladder carcinoma through the COX-2/PGE2/IDO1 Axis
Ouyang, Y., Zhong, W., Xu, P., Wang, B., Zhang, L., Yang, M., Chen, J., Li, H., Li, S., Chen, X., et al. (2024) · British Journal of Cancer · doi:10.1038/s41416-023-02552-z · Cited by 49
Immune Determinants of the Association between Tumor Mutational Burden and Immunotherapy Response across Cancer Types
Sinha, N., Sinha, S., Valero, C., Schäffer, A. A., Aldape, K., Litchfield, K., Chan, T. A., Morris, L. G. T., & Ruppin, E. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-2542 · Cited by 51
Self-citation
Abscopal Effects of Local Radiotherapy Are Dependent on Tumor Immunogenicity
Lai, J., Zhu, Y., Liu, Y., Zhou, L., Hu, L., Chen, L., & Zhang, Q. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.690188 · Cited by 47
Targeting neutrophils for cancer therapy
Kwak, J., & Houghton, A. M. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01210-8 · Cited by 54
Systemic and local immunosuppression in glioblastoma and its prognostic significance
Stepanenko, A. A., Sosnovtseva, A. O., Valikhov, M. P., Chernysheva, A. A., Abramova, O. V., Ka, P., & Chekhonin, V. P. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1326753 · Cited by 48
Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: A multicenter analysis
Chuma, M., Uojima, H., Hattori, N., Arase, Y., Fukushima, T., Hirose, S., Kobayashi, S., Ueno, M., Tezuka, S., Iwasaki, S., et al. (2021) · Hepatology Research · doi:10.1111/hepr.13732 · Cited by 44
Induction chemoimmunotherapy followed by CD8+ immune cell-based patient selection for chemotherapy-free radioimmunotherapy in locally advanced head and neck cancer
Hecht, M., Eckstein, M., Rutzner, S., von der Grün, J., Illmer, T., Klautke, G., Laban, S. A., Hautmann, M., Brunner, T. B., Tamaskovics, B. F., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003747 · Cited by 46
Pre-treatment serum albumin and mutational burden as biomarkers of response to immune checkpoint blockade
Yoo, S., Chowell, D., Valero, C., Morris, L. G. T., & Chan, T. A.-T. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00267-7 · Cited by 43
Self-citation
Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patients
Farina, B., Ramos-Guerra, A. D., Bermejo-Peláez, D., Miras, C. P., Peral, A. A., Madueño, G. G., Jaime, J. C., Vilalta, A., Rubio, J., Muñoz‐Barrutia, A., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04004-x · Cited by 43
Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naïve Stage IV PD-L1+ Non–Small Cell Lung Cancer Patients
Zhou, X., Zhou, L., Yao, Z., Huang, M., Gong, Y., Zou, B., Zhu, J., Liu, Y., Peng, F., Zhang, Y., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0315 · Cited by 43
Self-citation
The combination treatment of oncolytic adenovirus H101 with nivolumab for refractory advanced hepatocellular carcinoma: an open-label, single-arm, pilot study
Yi, L., Ning, Z., Xu, L., Shen, Y. L., Zhu, X., Yu, W., Xie, J., & Meng, Z. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.102239 · Cited by 41
Prognostic and predictive value of neutrophil-to-lymphocyte ratio with adjuvant immunotherapy in stage III non-small-cell lung cancer
Bryant, A. K., Sankar, K. N., Strohbehn, G. W., Zhao, L., Elliott, D., Qin, A., Yentz, S. E., Ramnath, N., & Green, M. D. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.11.021 · Cited by 39
Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
Thummalapalli, R., Ricciuti, B., Bandlamudi, C., Muldoon, D. M., Rizvi, H. A., Elkrief, A., Luo, J., Alessi, J. V., Pecci, F., Lamberti, G., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1207 · Cited by 38
Self-citation
Beyond binary: bridging neutrophil diversity to new therapeutic approaches in NSCLC
Horvath, L., Puschmann, C., Scheiber, A., Martowicz, A., Sturm, G., Trajanoski, Z., Wolf, D. G. F., Pircher, A., & Salcher, S. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.01.010 · Cited by 39
Association of systemic inflammatory markers and tertiary lymphoid structure with pathological complete response in gastric cancer patients receiving preoperative treatment: a retrospective cohort study
Wu, Y., Zhao, J., Wang, Z., Liu, D., Tian, C., Ye, B., Sun, Y., Li, H., & Wang, X. (2023) · International Journal of Surgery · doi:10.1097/js9.0000000000000741 · Cited by 40
The Combination of Radiotherapy With Immunotherapy and Potential Predictive Biomarkers for Treatment of Non-Small Cell Lung Cancer Patients
Lu, M., Xu, J., Ye, Y., Wang, Y., Luo, S., & Gong, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.723609 · Cited by 36
Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial
Bilen, M. A., Rini, B. I., Voss, M. H., Larkin, J., Haanen, J. B. A. G., Albiges, L. K., Pagliaro, L. C., Voog, É., Lam, E. T., Kislov, N. V., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1688 · Cited by 36
Circulating inflammatory cells in patients with metastatic breast cancer: Implications for treatment
Gianni, C., Palleschi, M., Schepisi, G., Casadei, C., Bleve, S., Merloni, F., Sirico, M., Sarti, S., Cecconetto, L., Menna, G. D., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.882896 · Cited by 40
Circulating and Tumor-Associated Neutrophils in the Era of Immune Checkpoint Inhibitors: Dynamics, Phenotypes, Metabolism, and Functions
Gibellini, L., Borella, R., Santacroce, E., Serattini, E., Boraldi, F., Quaglino, D., Aramini, B., Biasi, S. D., & Cossarizza, A. (2023) · Cancers · doi:10.3390/cancers15133327 · Cited by 35
A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma
Rappold, P. M., Vuong, L. H., Leibold, J., Chakiryan, N. H., Curry, M., Kuo, F., Sabio, E. Y., Jiang, H., Nixon, B. G., Liu, M., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0925 · Cited by 36
Self-citation
Pretrained transformers applied to clinical studies improve predictions of treatment efficacy and associated biomarkers
(2025) · doi:10.1038/s41467-025-57181-2 · Cited by 34
Harnessing the immunotherapeutic potential of CDK4/6 inhibitors in melanoma: is timing everything?
Lelliott, E. J., Sheppard, K. E., & McArthur, G. A. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00273-9 · Cited by 34
Associations between systemic inflammation indicators and nonalcoholic fatty liver disease: evidence from a prospective study
Gong, H., He, Q., Zhu, L., Feng, Z., Sun, M., Jiang, J., Yuan, X., Shen, Y., & Di, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1389967 · Cited by 33
Pretreatment absolute lymphocyte count is an independent predictor for survival outcomes for esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy and pembrolizumab: An analysis from a prospective cohort
Qi, W., Wang, X., Li, C., Li, S., Li, H., Xu, F., Chen, J., Zhao, S., & Li, H. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.14898 · Cited by 33
Differential prognostic effect of systemic inflammation in patients with non–small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial
Cortellini, A., Ricciuti, B., Borghaei, H., Naqash, A. R., D’Alessio, A., Fulgenzi, C. A. M., Addeo, A., Banna, G. L., & Pinato, D. J. (2022) · Cancer · doi:10.1002/cncr.34348 · Cited by 31
Prognostic roles of hematological indicators for the efficacy and prognosis of immune checkpoint inhibitors in patients with advanced tumors: a retrospective cohort study
Zheng, F., Meng, Q., Zhang, L., Chen, J., Zhao, L., Zhou, Z., & Liu, Y. (2023) · World Journal of Surgical Oncology · doi:10.1186/s12957-023-03077-8 · Cited by 30
Prognostic value of nutritional and inflammatory markers in patients with hepatocellular carcinoma who receive immune checkpoint inhibitors
Liu, C., Zhao, H., Zhang, R., Guo, Z., Wang, P., & Qu, Z.-W. (2023) · Oncology Letters · doi:10.3892/ol.2023.14024 · Cited by 31
Challenges and Future Directions in the Management of Tumor Mutational Burden-High (TMB-H) Advanced Solid Malignancies
Ahmed, J., Das, B., Shin, S. J., & Chen, A. P. (2023) · Cancers · doi:10.3390/cancers15245841 · Cited by 36
Negative association of steroids with immunotherapy efficacy in a multi-tumor cohort: time and dose-dependent
Albarrán, V., Guerrero, P., de Quevedo, C. G., González-Merino, C., Chamorro, J. V., Rosero, D. I., Moreno, J., Calvo, J. C., de Aguado, P. P., Alía, V., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03772-9 · Cited by 30
Real-world outcomes of regorafenib combined with immune checkpoint inhibitors in patients with advanced or metastatic microsatellite stable colorectal cancer: A multicenter study
Yang, K., Han, L., Wu, S., Qu, X., Li, Q., Zhao, C., Zhou, J., Jin, X. S., Wang, Y., Dong, Y., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03083-3 · Cited by 30
Neutrophils: Musketeers against immunotherapy
Zahid, K. R., Raza, U., Tumbath, S., Jiang, L., Xu, W., & Huang, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.975981 · Cited by 31
Fibrinogen-like 2 in tumor-associated macrophage-derived extracellular vesicles shapes an immunosuppressive microenvironment in colorectal liver metastases by promoting tumor stemness and neutrophil extracellular traps formation
Zhou, M., Guan, B., Liu, Y., Gu, Q., Chen, W. T., Xie, B., Zhou, M., Xiang, J., Zhao, S., Zhao, Q., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217642 · Cited by 29
Nomogram Based on Inflammatory Biomarkers and Nutritional Indicators for Predicting Overall Survival in Locoregionally Advanced Nasopharyngeal Carcinoma
Zhao, R., Liang, Z., Chen, K.-H., & Zhu, X. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s366299 · Cited by 29
Next-generation sequencing: unraveling genetic mechanisms that shape cancer immunotherapy efficacy
Halima, A., Vuong, W., & Chan, T. A.-T. (2022) · Journal of Clinical Investigation · doi:10.1172/jci154945 · Cited by 31
Self-citation
Neutrophil-to-Lymphocyte Ratio Is a Major Prognostic Factor in Non-small Cell Lung Carcinoma Patients Undergoing First Line Immunotherapy With Pembrolizumab
Romano, F. J., Ronga, R., Ambrosio, F., Arundine, D., Longo, V., Galetta, D., Gridelli, C., Maione, P., PALMA, V., Damiano, V., et al. (2022) · Cancer Diagnosis & Prognosis · doi:10.21873/cdp.10178 · Cited by 28
Biomarkers for predicting tumor response to PD-1 inhibitors in patients with advanced pancreatic cancer
Qiu, X., Shi, Z., Tong, F., Lu, C., Zhu, Y., Wang, Q.-L., Gu, Q., Qian, X., Meng, F., Liu, B., et al. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2178791 · Cited by 28
Systemic inflammation shapes clinical outcomes in response to immune checkpoint blockade treatment: moving toward optimizing antitumor immunity
Zheng, M. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006462 · Cited by 28
Immune checkpoint inhibitors promising role in cancer therapy: clinical evidence and immune-related adverse events
Meybodi, S. M., Far, B. F., Pourmolaei, A., Baradarbarjastehbaf, F., Safaei, M., Mohammadkhani, N., & Samadani, A. A. (2023) · Medical Oncology · doi:10.1007/s12032-023-02114-6 · Cited by 28
The neutrophil–lymphocyte ratio: considerations for clinical application
Adamstein, N. H., & Ridker, P. M. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab166 · Cited by 27
Overcoming anti-PD-1/PD-L1 immune checkpoint blockade resistance: the role of macrophage, neutrophils and mast cells in the tumor microenvironment
Kwantwi, L. B. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01059-4 · Cited by 27
Javelin Head Neck 100: Should we combine immunotherapy with radiation therapy?
Yu, Y., Zakeri, K., & Lee, N. (2021) · Oncotarget · doi:10.18632/oncotarget.27987 · Cited by 27
Self-citation
Body mass index and adiposity influence responses to immune checkpoint inhibition in endometrial cancer
Gómez-Banoy, N., Ortiz, E. J., Jiang, C. S., Dagher, C., Sevilla, C., Girshman, J., Pagano, A., Plodkowski, A. J., Zammarrelli, W. A., Mueller, J. J., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci180516 · Cited by 30
Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy
Wang, T., Denman, D., Bacot, S. M., & Feldman, G. M. (2022) · Biomedicines · doi:10.3390/biomedicines10051181 · Cited by 27
Prognostic Effect of the Controlling Nutritional Status Score in Patients With Esophageal Cancer Treated With Immune Checkpoint Inhibitor
Chang, L., Cheng, Q., Ma, Y., Wu, C., Zhang, X., Ma, Q., He, L., Li, Q., & Ji, T. (2022) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000438 · Cited by 26
Association of inflammatory markers with survival in patients with advanced gastric cancer treated with immune checkpoint inhibitors combined with chemotherapy as first line treatment
Wan, M., Ding, Y., Mao, C., Ma, X., Li, N., Cheng, X., Qian, J., Jiang, H., Zheng, Y., Wu, L., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1029960 · Cited by 26
Prolonged survival of anaplastic thyroid carcinoma is associated with resectability, low tumor-infiltrating neutrophils/myeloid-derived suppressor cells, and low peripheral neutrophil-to-lymphocyte ratio
Xu, B., Zhang, L., Setoodeh, R., Mohanty, A. S., Landa, I., Balzer, B. L., Tiedje, V., Ganly, I., Doğan, S., Fagin, J. A., et al. (2022) · Endocrine · doi:10.1007/s12020-022-03008-9 · Cited by 23
Self-citation
High Blood Concentration of Leukocyte-Derived Extracellular Vesicles Is Predictive of Favorable Clinical Outcomes in Patients with Pancreatic Cancer: Results from a Multicenter Prospective Study
Brocco, D., Bellis, D. D., Marino, P. D., Simeone, P., Grassadonia, A., Tursi, M. D., Grottola, T., di Mola, F. F., Gregorio, P. D., Zappacosta, B., et al. (2022) · Cancers · doi:10.3390/cancers14194748 · Cited by 25
Senescent neutrophils: a hidden role in cancer progression
Rys, R. N., & Calcinotto, A. (2024) · Trends in Cell Biology · doi:10.1016/j.tcb.2024.09.001 · Cited by 26

Authors: Valero, C., Lee, M., Hoen, D., Weiss, K., Kelly, D. W., Adusumilli, P. S., Paik, P. K., Plitas, G., Ladanyi, M., Postow, M. A., Ariyan, C. E., Shoushtari, A. N., Balachandran, V. P., Hakimi, A. A., Crago, A. M., Long Roche, K. C., Smith, J. J., Ganly, I., Wong, R. J., Patel, S. G., Shah, J. P., Lee, N. Y., Riaz, N., Wang, J., Zehir, A., Berger, M. F., Chan, T. A., Seshan, V. E., & Morris, L. G. T.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
Corresponding author: Chan, Timothy A.
Seshan, Venkatraman E.
Morris, Luc G. T.
ORCID: Valero, Cristina
Lee, Mark
Weiss, Kate
Kelly, Daniel W.
Adusumilli, Prasad S.
Paik, Paul K.
Plitas, George
Ladanyi, Marc
Postow, Michael A.
Ariyan, Charlotte E.
Shoushtari, Alexander N.
Balachandran, Vinod P.
Hakimi, A. Ari
Crago, Aimee M.
Smith, J. Joshua
Ganly, Ian
Wong, Richard J.
Patel, Snehal G.
Shah, Jatin P.
Lee, Nancy Y.
Riaz, Nadeem
Wang, Jingming
Zehir, Ahmet
Berger, Michael F.
Chan, Timothy A.
Seshan, Venkatraman E.
Morris, Luc G. T.
Venue: Nature Communications
Publisher: Springer Science and Business Media LLC
Published: 2021-02-01
Volume: 12
Issue: 1
Pages: 729-729
ISSN: 2041-1723 (ISSN-L)
DOI: 10.1038/s41467-021-20935-9
PMC: PMC7851155
OpenAlex: W3127371144
Cited by: 441
References: 57
Citations by year: 2026: 53 · 2025: 74 · 2024: 116 · 2023: 92 · 2022: 80 · 2021: 26
FWCI: 28.60
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0 (tdm)
creativecommons.org/licenses/by/4.0 (vor)
Locations: Nature Communications (publishedVersion, cc-by)
Europe PMC (PubMed Central) (publishedVersion, other-oa)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
RePEc: Research Papers in Economics (submittedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders: Fundación Alfonso Martín Escudero (N/A)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA205426, R35 CA232097)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Oncology › Inflammatory Biomarkers in Disease Prognosis
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
Keywords: immune checkpoint inhibitors, neutrophil-to-lymphocyte ratio, tumor mutational burden, predictive biomarkers, tumor response, overall survival, progression-free survival, cancer immunotherapy, prognostic factors
MeSH terms: Progression-Free Survival, Immune Checkpoint Inhibitors, Aged, Female, Follow-Up Studies, Humans, Lymphocytes, Male, Middle Aged, Neoplasms, Neutrophils, Predictive Value of Tests, Retrospective Studies, Lymphocyte Count, Drug Resistance, Neoplasm, Mutation Rate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks